This big ticket deal in the pharma space is also the first M&A transaction to have gone through public scrutiny amid concerns of adverse impact on fair competition in the market.
"We will be finalising our order and a decision on that within the next week or so. It is at a very advanced stage and our people are engaging with the companies and their representatives. The final order will be available before the end of this month," Competition Commission of India (CCI) Chairman Ashok Chawla said here today.
Sun Pharma-Ranbaxy transaction, which would create the country's largest pharmaceutical company, had come under close scrutiny of CCI after it was found prima-facie that the "combination is likely to have an appreciable adverse effect on competition.
The combined entity would have operations in 65 countries, 47 manufacturing facilities across 5 continents, and a significant platform of speciality and generic products marketed globally. The deal, announced in April this year, is also the first one where Commission sought public comments.
The public scrutiny of the deal, which would create the fifth largest speciality generics company in the world, ended on September 24. Major issues being examined by CCI on the deal are with respect to the molecules market.
"We are obliged to look at it but I am not sure at what stage the examination is and we are not certainly at any position where we can decide one way or the other," he said.
He, however, did not disclose any specific details.
Chawla was speaking to reporters on the sidelines of Skoch Summit.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
